Company Overview of Universite Libre de Bruxelles in Belgium
Universite Libre de Bruxelles in Belgium is an educational institution.
Key Executives for Universite Libre de Bruxelles in Belgium
Universite Libre de Bruxelles in Belgium does not have any Key Executives recorded.
Universite Libre de Bruxelles in Belgium Key Developments
Universite Libre de Bruxelles and ChromaDex Corporation to Collaborate on NIAGEN(TM) Nicotinamide Riboside Research
Nov 5 13
ChromaDex Corp. announced it has entered into a material transfer agreement (MTA) with Universite Libre de Bruxelles, whereby ChromaDex will provide ULB with quantities of its recently launched NIAGEN(TM) nicotinamide riboside (NR). Dr. Oberdan Leo, with the help of Drs. Fabienne Andris, Anthony Rongvaux and Frederic Van Gool at the Universite Libre de Bruxelles, identified the mammalian gene encoding for nicotinamide phosphoribosyl tranferase (Nampt), the rate limiting enzyme in the biosynthetic pathway linking nicotinamide (a major component of Vitamin B3) to NAD. The group led by Dr. Leo later demonstrated that this biosynthetic pathway plays an important role in lymphocyte development and in the regulation of innate immunity. ChromaDex's NIAGEN(TM) has the potential to be a next generation niacin (Vitamin B3) and become part of the portfolio of B-vitamin ingredients that are included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, infant formula, food and beverage products. NIAGEN(TM) is the first and only commercially available brand of NR. Over the past two years, ChromaDex has built a significant patent portfolio pertaining to NR by separately acquiring patent rights from Cornell University, Dartmouth College and Washington University. ChromaDex believes its patent rights create a significant and meaningful barrier to entry for would-be competitors in the NR market.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries